Uloga perkutane slikovno vođene ablacije malignih tumora jetre: svjetski trendovi i hrvatska perspektiva by Luka Novosel & Dijana Zadravec
6original scientific paper libri oncol. 2019;47(1):6–12
 doi: 10.20471/lo.2019.47.01.02
ROLE OF PERCUTANEOUS IMAGE-GUIDED ABLATION  
OF MALIGNANT LIVER TUMORS:  
GLOBAL TRENDS AND CROATIAN PERSPECTIVE
lUKa noVosel and DiJana ZaDraVec
Division of Diagnostic and interventional radiology,  
sestre milosrdnice University Hospital center, Zagreb, croatia
Summary
percutaneous minimally invasive methods are gaining space in oncologic treatment algorithms. interventional radiol-
ogy has a leading role in the last twenty years in developing percutaneous curative therapy for tumors of the parenchymal 
organs of the abdomen due to the precision of image-guided procedures. ablative technology uses thermal energy for 
 tumor tissue destruction. compared to radiofrequency technology, microwave technology shows advantages in size of the 
liver tumors that can be ablated and the length of the procedure. compared to surgery, both ablative techniques, enable 
shorter postprocedural time to chemotherapy, hospital stay and recovery time, reduced complication rate, and easier 
 secondary ablation in case of new or residual tumors. comparative advantages make these minimally invasive procedures, 
often the first choice in the treatment of hepatocellular carcinoma and liver metastases. Even though image-guided ablation 
is accepted in most european countries as a valid alternative to surgery in patients with unresectable hepatic tumors, cur-
rently, there is no algorithm for the use of this minimally invasive therapy in croatia. lack of clinical validation of thermal 
ablation in croatia is mostly due to a limited number of the interventional radiologist with such focus along with limited 
patient referrals despite the published data about the potential advantages, efficacy, and safety of this technology.
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ULOGA PERKUTANE SLIKOVNO VOĐENE ABLACIJE MALIGNIH TUMORA JETRE:  
SVJETSKI TRENDOVI I HRVATSKA PERSPEKTIVA
Sažetak
Perkutane minimalno invazivne metode u dobivaju sve veću ulogu u algoritmu liječenja onkoloških pacijenata. Inter-
vencijska radiologija kontinuirano razvija perkutane kurativne terapije parenhimskih organa abdomena zadnjih 20 godina, 
prije svega zbog napretka u preciznosti terapije vođene slikovnim metodama. Ablativna tehnologija koristi toplinsku ener-
giju za destrukciju tumora. U usporedbi s radiofrekventnom tehnologijom, mikrovalna tehnologija je indicrana i za veće 
tumore jetre uz kraće vrijeme zahvata. U usporedbi s kirurškim zahvatima, ablativne tehnike omogućavaju kraće vrijeme 
hospitalizacije i oporavka, manju stopu komplikacija i mogućnost lakšeg ponavljanja zahvata u slučaju recidiva kao i brži 
nastavak liječenjadrugimmodalitetima primjerice kemoterapijom. Stoga su ove minimalno invazivne procedure sve češće 
metoda izbora u liječenju hepatocelularnog karcinoma i jetrenih metastaza. Iako je perkutana slikovno vođena ablacija pri-
hvaćena u većini europskih zemalja kao vrijedna alternativa kirurgiji za liječenje pacijenata s resektabilnim tumorom jetre, 
trenutno u Hrvatskoj ne postoji prihvaćeni algoritam za korištenje ove minimalno invazivne terapije. Slabo kliničko vredno-
vanje termalne ablacije u Hrvatskoj je ponajprije posljedica postupnog povećanja broja intervencijskih radiologa u tom polju 
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i relativno slabog upućivanja pacijenata unatoč dostupnosti publiciranih podataka o prednostima, učinkovitosti i sigurnosti 
ove tehnologije.
KLJUČNE RIJEČI:  perkutana ablacija, slikovno vođene terapije metastatski kolorektalni karcinom, hepatocelularni karcinom, jetra, 
intervencijska radiologija
INTRODUCTION
image-guided thermal ablation is used to treat 
a variety of liver tumors, ranging from focal prima-
ry hepatocellular carcinoma to metastatic colorectal 
and non-colorectal liver metastases (1–3). When 
compared to surgical resection advantages of per-
cutaneous ablation include lower associated mor-
bidity and mortality, the possibility of use in pa-
tients who are not surgical candidates, shorter re-
covery with greater cost-effectiveness (4,5).
colorectal cancer is the third most common 
malignancy in the world, and fifty percent of pa-
tients develop liver metastases (6). the develop-
ment of hepatic metastases is the leading cause of 
death in patients with colorectal carcinoma. How-
ever, only up to 15% of these patients are candi-
dates for surgical resection. five-year survival af-
ter liver resection ranges from 30% and 58% while 
data suggests that after ablation survival varies 
from 17 to 51% (7, 8). The remainder of the pa-
tients treated with chemotherapy has a five-year 
survival remaining close to 0% (7,8).
Hepatocellular carcinoma (Hcc) is currently 
the second leading cause of cancer-related death; 
its incidence and mortality rates are increasing 
(9,10). even though surgical resection has the best 
long term results and survival, only a minority of 
Hcc patients are surgical candidates, mostly due 
to comorbidities, liver function, lesion size or loca-
tion and extrahepatic disease progression (9,10). 
percutaneous thermal ablation is recommended in 
the treatment of nonsurgical patients with early-
stage Hcc and metastatic disease limited only to 
the liver when these tumors are limited in size and 
number.
Most developed countries have accepted the 
existing quality improvement guidelines and ex-
pert position statements and recommendations, 
but there is still a lack of high value published evi-
dence which would support clinical validation 
and creation of algorithms involving thermal ab-
lation therapy of malignant liver tumors.
another issue is that the existing recommen-
dations usually cover only radiofrequency abla-
tion (rfa) since it is the oldest, thereby the only 
thermal ablation technique with sufficient data for 
evidence-based approach (11,12). However, rfa 
as therapy has known limitations such as ablation 
volume, predictability of ablation zone, and dura-
tion of the procedure.
recently, new ablative technologies have 
emerged for focal tissue destruction. since they 
overcame some of the rfa limitations, these tech-
nologies soon entered the common practice (13-
15). Microwave ablation (MWA) is a heat-based 
technology which uses specific wavelengths to 
achieve high temperatures in tissues, and as it 
continues to improve with newer devices, it is 
slowly taking over the leading role in the liver 
from rfa (16,17).
Both rfa and MWa are thermal ablation 
techniques that use electromagnetic energy to 
cause rotation of water molecules. tumor cells 
around the probe undergo denaturation of intra-
cellular proteins and cell membranes. MWa 
spreads energy from the probe tip through the tis-
sue and heats the tissue as waves attenuate which 
leads to deposition of energy in a larger volume 
than with rfa since electromagnetic energy re-
quires no direct current flow, it overcomes the 
limitations of rfa regarding carbonization and 
evaporation of the tissue. one of the main advan-
tages of MWa over rfa is avoiding the heat-sink 
effect or drain of energy on large vessels which are 
usually a relative contraindication for therapy 
with RFA when in the proximity of tumors (18). 
MWa also provides higher intratumoral tempera-
tures, which can help treat cystic lesions, also 
sometimes problematic for treatment with rfa.
general lack of comprehensive understand-
ing of the possible advantages of percutaneous 
ablation and shortage of interventional radiolo-
gists performing percutaneous non-vascular on-
cologic treatment methods has led to percutane-
ous ablative therapies being systematically in-
volved in oncological treatment protocols much 
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later and to a lesser extent in croatia than in other 
developed countries. We started with percutane-
ous ct guided radiofrequency and microwave ab-
lation in 2017 at our cancer center and since then 
we performed 56 ablations of malignant liver tu-
mors, predominantly colorectal liver metastases, 
but also Hcc and other liver metastases.
INDICATIONS FOR LIVER ABLATION
indications for tumor ablation in any organ 
can be curative or palliative. Most of the recom-
mendations and expert opinions revolve around 
curative intent in the liver tumors. the ablation is 
observed as an alternative method to surgery in 
achieving complete eradication of tumor tissue in 
patients who are not good surgical candidates. 
the ablation is also indicated for palliation, where 
it reduces tumor mass and achieves symptom re-
lief and reduced risk of complications caused by 
the tumor progression.
One of the first society guidelines to incorpo-
rate ablation into its algorithm was the Barcelona 
clinic liver cancer (Bclc) staging and treatment 
for Hcc. in it, ablation is recommended as the 
treatment of choice for early stages of Hcc, stage 
0 (single lesion smaller than 2 cm, Child-Pugh A, 
pso 0), for patients who are not potential candi-
dates for liver transplantation. for Bclc stage a 
patient surgical resection, liver transplantation, 
and ablation are the recommended lines of treat-
ment. the american association of the study of 
the liver Disease (aaslD) also has recommenda-
tions for ablation which include early-stage Hccs, 
smaller than 3 cm in size and less than three le-
sions, or cases of early-stage HCCs smaller than  
2 cm but with additional complications such as 
portal hypertension. surgery is still the standard 
of care in patients without complications such as 
portal hypertension, cirrhosis or high bilirubin, 
and early-stage Hcc. these recommendations 
only mention rfa. nevertheless, the studies 
proved that MWa has the same potential with 
possible added benefits and is often used in HCC 
treatment instead of rfa (19).
for liver metastases of colorectal cancer, indi-
cations are somewhat different than in HCC. In 
patients with colorectal liver metastases, up to 
5 cm in size and/or with less than five liver lesions 
we consider ablation therapy, but individual pa-
tient and tumor characteristics are (19,20). in co-
lorectal liver metastases ablation, specifically, 
MWa provides comparable results to surgery 
with 1, 2 and 3-year survival rates and mean sur-
vival times were 69 %, 56 %, 23 %, and 25 months 
after surgery and 71 %, 57 %, 14 %, and 27 months 
after MWa (21).
relative and absolute contraindications for 
percutaneous ablative therapy in the liver include 
coagulation dysfunction, high extrahepatic tumor 
burden, liver failure with ascites, hepatic encepha-
lopathy or other organ failures, tumor volume 
> 70 % of the liver volume, active inflammation. 
Unlike in rfa, metallic foreign objects and pace-
makers are not a contraindication for MWa (22).
ABLATION RESULTS IN THE LITERATURE:
existing guidelines for Hcc therapy put ab-
lation before surgery in small or very small Hccs 
smaller than 3 cm because ablation has shown to 
cause much less loss in the normal liver parenchy-
ma compared to surgical resection and is associ-
ated with fewer complications. shorter recovery 
time is sometimes crucial for receiving the chemo-
therapy within an optimal timeframe.
a retrospective study by Zhang compared 
percutaneous rfa to MWa in Hccs smaller than 
5 cm in 155 patients. Technical success was achieved 
in 83.4% RFA and 86.7% MWA treated patients. 
There was no significant difference in the 1, 3 and 
5-year overall survival and the 1, 3 and 5-year dis-
ease-free survival rates between the rfa and MWa 
groups (23). furthermore, ultrasound-guided 
MWa was performed in 107 patients with large 
HCCs with a technical success rate of 98.13% (24). 
large Hcc can be treated both with MWa and 
with chemoembolization, but this is sometimes 
considered a palliative indication. a comparison of 
the two methods showed that MWa had a lower 
incidence of recurrence with higher rates of com-
plete ablation (75%) (25). However, a prospective 
study involving patients with Hcc smaller than 
7 cm in diameter compared outcomes after rfa or 
MWa alone or in combination with tace. it 
showed that combination therapies had superior 
survival compared to rfa or MWa alone (26).
Medium-sized single Hcc tumors were 
treated in 182 patients in a study that showed 
technical rate of effectiveness of 93% and the re-
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currence-free survival and overall survival rates 
at 1, 2 and 3 years to be 51%, 36%, 27% and 89%, 
74%, 60%, respectively (27).
percutaneous ablation therapy in Hcc shows 
technical success rates ranging from 86 to 95% 
and progression-free survival of 91.7% for small 
lesions. One, 3 and 5-year survival rates following 
ablation ranges between 89–94%, 54–74% and 
43–60%.
in liver metastases, there are a few interest-
ing studies investigating the efficacy and compli-
cations of MWa. sixty-four patients with a single 
liver metastasis including colorectal cancer, breast 
cancer, carcinoid, melanoma, lung cancer, and 
anal cancer were followed for nine years after 
MWA ablation. The technical success rate of 95% 
was reported. the survival rates were 36.3 months 
for colorectal cancer metastases, and 13.9 months 
for other types compared to 38.3 months in HCC 
patients. When local recurrence at one year after 
ablation was observed there was a recurrence rate 
of 45.7% in colorectal metastases and 70.8% in 
 other metastases compared to 39.8% in HCC.
Thermal ablation is very effective in treating 
small to medium-sized metastatic tumors. Many 
series reported trying to treat metastases over 5 
cm, up to 11 or 12 cm, but the incomplete ablation 
and local recurrence rates were high. the most 
common cut-off point is 3 cm (28,29). However, 
tumors up to 5 cm can be ablated completely if 
their localization is accessible, and the proper pro-
tocol is applied. Hammil (29) reported a 3% local 
recurrence rate for tumors smaller than 3 cm and 
4% recurrence for 3 to 5 cm tumours, while recur-
rence rates for tumors larger than 5 cm remained 
higher, ranging from 27 to 45% and therefore abla-
tion with curative intent should not be recom-
mended for metastases over 5 cm.
OUR CENTER EXPERIENCE:
We started with percutaneous ct guided ra-
diofrequency and microwave ablation in 2017 at 
our cancer center and since then we performed 56 
ablations of malignant liver tumors, predominant-
ly colorectal liver metastases, but also Hcc and 
other liver metastases.
all included patients at our institution were 
indicated for percutaneous thermal ablation of the 
liver by a multidisciplinary tumor team (MDt), 
which included surgeons, radiologists, and oncol-
ogists. With MDt’s recommendation, the consul-
tant surgeon and the interventional radiologist 
would explain possible treatment options and 
their risks to the patient. the patient was also in-
formed about the need for long term ct or Mri 
follow-up that is required in the case of ablation 
therapy. the patients that accepted the treatment 
with percutaneous ablation were then included in 
the treatment protocol. inclusion criteria for abla-
tion in terms of the size of the lesion were depen-
dent on the individual treatment strategy. Both 
curative ablations of small Hcc and metastases 
(up to 5 cm) were performed but also palliative ab-
lation of lesions over 5cm and multiple lesions or 
lesions with present extrahepatic spread, when ad-
ditional extrahepatic therapy was planned. from 
January 2017 until May 2019, 56 patients were 
treated, 6 with RFA and 50 with MWA. There were 
9 HCC treated, 38 colorectal metastases, 3 breast 
cancer metastases, 2 ovarian cancer metastases, 1 
rcc metastasis, and 3 cholangiocarcinomas.
all patients underwent routine baseline labo-
ratory investigations, including coagulation pa-
rameters (international normalized ratio [INR] <1.5 
was required at the time of treatment and platelet 
count >50000), renal function tests (serum creati-
nine and urea measurement) and full blood count.
as advised by the international guidelines all 
patients had an abdominal computed tomogra-
phy (ct) or magnetic resonance (Mr) imaging 
performed at least 4 weeks prior to treatment. six 
patients required a biopsy prior to ablation to con-
firm the diagnosis. The biopsy was performed in a 
prior session in all patients.
CT-GUIDED RFA AND MWA PROCEDURE
rfa was performed under general anesthe-
sia in all patients. the procedure was performed 
with the olympus celon radiofrequency device 
with bipolar internally cooled electrodes, using 
one to three 10-15 cm electrodes at once depend-
ing on the size of the lesion. local anesthesia was 
always used (1% Lidocaine). The MWA procedure 
was performed under general anesthesia in pa-
tients with multiple lesions treated all at once or 
when the tumor size was over 3 cm. smaller single 
lesions were treated under moderate sedation, 
and all received local anesthesia (1% Lidocaine). 
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the microwave unit from Hs amica is capable of 
producing 100W of power at 2450MHz. The cool-
tip needle antenna has a diameter of 1.9 mm (14 
gauge) and a length of 10-20 cm. the antenna was 
percutaneously inserted into the tumor and placed 
at the desired location under ct guidance. a pow-
er output of 60-100 W was applied from 3 to 8 
minutes depending on the size of the lesion, al-
ways in one needle placement.
accurate imaging during ablation is essential 
for precise probe positioning, which proved to be 
one of the more crucial parts of the procedure in 
order to reduce complications and local recur-
rence. Using ultrasound monitoring during ther-
mal ablation can be helpful for real-time monitor-
ing, but there is a downside since usually, a hyper-
echogenic area appears early around the probe 
tip, which is caused by microbubbles and gas re-
leased from the heated tissue. this does not cor-
relate with tissue coagulation as once thought, 
and these gas bubbles in the liver parenchyma can 
affect evaluation by overestimating the size of the 
ablated areas. this phenomenon will often disap-
pear completely within one hour after ablation. 
therefore, we monitor the positioning of the MWa 
antenna and the procedure under ct, which al-
lows precise visualization of the vaporization pro-
cess and early detection of possible complications, 
like bleeding or pneumothorax.
in 3 patients, we also used hydrodissection 
with 0.9 % saline with a small amount of contrast 
injected between the targeted lesion and adjacent 
organs, usually the intestine in order to protect 
them from possible thermal damage.
FOLLOW-UP
the follow-up included routine postopera-
tive physical examination, laboratory tests, and a 
three-phase contrast-enhanced ct or dynamic 
Mri imaging at 1, 4 and 12 months after treat-
ment. Technique effectiveness was defined as the 
absence of enhancement of any residual areas of 
the lesion at a follow-up contrast-enhanced exam-
ination. Local recurrence was defined as the ap-
pearance of postcontrast enhancement more than 
20 H.U. in scattered, nodular, or eccentric pattern 
inside or around the ablation zone. interpreting 
post-ablation findings is sometimes not straight-
forward and demands a level of experience. a 
central zone of coagulation induced in most ther-
mal therapies is generally accepted to represent 
coagulated tissue. the coagulation zone is usually 
surrounded by a red zone of hyperemia. on de-
layed contrast images, peripheral rim enhance-
ment (< 20 HU) often surrounds the region of co-
agulation and indicates an inflammatory reaction 
due to thermally damaged cells. this can be either 
pseudoenhancement or represent minimal en-
hancement from leaky capillaries at the treatment 
margin. a bulky irregular rim at the edge of a 
treatment site is the most common appearance of 
an incompletely treated lesion.
RESULTS
From January 2017 to May 2019, 56 patients 
were treated at our institution, 6 with RFA, and 50 
with MWa. Mean age of the patients was 64 years 
± 12.9. of the 9 Hcc treated, the mean tumor size 
was 2,9 cm, with an average of 1,4 lesions. the 
procedure was technically effective in 77%, with 
three retreatments required due to local recur-
rence or new lesions. there was one case of minor 
hemorrhage that did not require intervention. +
the patients reported higher pain levels in 
the first 8 hours after treatment with MWA, which 
resolved within the first 24 hours with analgesia. 
the patients who underwent general anesthesia 
took a long time to recover after treatment, and 
one patient complained of neck pain and had a 
broken tooth due to intubation.
Metastatic tumors were predominantly colo-
rectal in origin, but there were also other carcino-
mas such as breast, rcc, ovarian, and cholangio-
carcinoma. lesion size was 3,2 cm on average, 
with 1,7 lesions treated per session. the local re-
currence rate was 23%, higher in lesions larger 
than 4 cm (up to 48%), while lesions measuring up 
to 2 cm in size had a local recurrence rate of 8%. 
there were two cases of serious complications re-
quiring additional surgical therapy: one case of 
jejunal perforation due to thermal injury and one 
case of biliary obstruction requiring biliary inter-
vention (30).
CONCLUSION
thermal ablation is becoming accepted 
worldwide as a possible first-line therapy for very 
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early Hcc, inoperable Hcc and oligonodular 
liver metastases smaller than 3 cm in selected pa-
tients with comorbidities. even though strong evi-
dence from prospective randomized controlled 
trials are not available, yet there is sufficient data 
that supports the use of percutaneous ct-guided 
ablation for a subgroup of liver carcinomas and 
metastases.
international guidelines for Hcc recom-
mend rfa due to the abundance of published evi-
dence compared to other technologies. the known 
advantages of MWa over rfa and surgery make 
this method a new tool in both inoperable and op-
erable primary and secondary liver tumors with 
the advantage of lower morbidity, mortality, and 
easier redo.
thermal ablation methods were long under-
estimated and overlooked in the oncological treat-
ment protocols in croatia due to multiple factors, 
but since 2017 rfa and MWa of liver tumors is an 
available treatment with initial results showing 
promising results.
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